We acknowledge the limitations of our study, including the retrospective design, the small sample size (due to the inclusion of patients from a single centre), the heterogeneous population and treatments, the pre-defined rounded cut-off values for PD-L1 expression, the exclusion of patients with pathological complete response from the analysis of PD-L1 expression by the TPS and CPS in surgical samples (neither can be calculated in the absence of viable tumour cells), and the risk of random findings due to the lack of statistical adjustment for multiple comparisons. This evidence concerns the gene CD274 and neoplasm.